Integragen
Go to content
  • Français
  • Areas of Interest
    • Clinical Research
    • Basic and Human Genetic Research
    • Agrigenomics
    • Microbial Genomics
  • Genomic services
    • Transcriptomics
    • Epigenomics
    • DNA Sequencing
    • NGS Test for Cancer Research
    • SNP Genotyping
  • Bioinformatics
    • MERCURY
    • SIRIUS
    • GALILEO
    • GECO
  • About Us
    • Company Overview
    • Management Team
    • Careers
      • QA Engineer (Evry, France)
      • QA Group Manager (Gosselies, Belgium – Evry, France)
    • Board of Directors
  • News and Events
    • Press Releases
    • Latest News
    • Scientific publications
    • Upcoming Events
      • Belgian Society for Human Genetics (BeSHG)
      • SÉMINAIRE DE GÉNÉTIQUE CLINIQUE À ANGERS
  • Investors
    • Shareholder Meetings
    • Corporate Presentations
    • Number of Shares and Voting Rights
    • Liquidity Contract Reactivation
    • Press Releases
    • Share Information
    • Calendar for Publications
    • OncoDNA Friendly Takeover Bid
    • Investor Contacts
    • Receive Updates About IntegraGen
    • Financial Documents
      • Financial Reports
      • Liquidity Contract
  • Contact Us
    • Office Location
      • Need Directions?
    • Request a Demo
    • Contact Us
    • Receive Updates About IntegraGen
Home » News and EventsPage 8

News and Events

10 October 2016

New Data on IntegraGen’s miR-31-3p Biomarker Featured in Presentation at 2016 ESMO Congress

Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.

Click here to view press release

04 October 2016

IntegraGen to participate in ODDO Forum being held in Lyon, France

IntegraGen will be participating in the ODDO Forum being held at the Lyon Convention Center on 5 and 6 January 2017.

View the meeting program

 

 

03 October 2016

IntegraGen to present on ICE Project during Medicen Paris Region Meeting

IntegraGen will present an update on the ICE Project (Interpretation of Clinical Exome) during the MEDICEN PARIS REGION meeting being held on Wednesday, October 5, 2016 at the headquarters of Bpifrance. This meeting will be attended by the organization’s members, partners and (…)  » 

04 September 2016

New data on miR-31-3p biomarker to be featured during oral presentation at 2016 ESMO Congress

Results from a new analysis of the predictive miR 31-3p biomarker for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial will be featured as an oral presentation during a proffered session at the upcoming 2016 European Society of Medical Oncology (ESMO) Congress. Professor Pierre Laurent-Puig, (…)  » 

07 July 2016

IntegraGen reports strong revenue growth during first half of 2016

IntegraGen has announced its sales for the first half 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.

Link to press release

29 June 2016

AP-HP and IntegraGen agree to develop a common platform for high-throughput sequencing

AP-HP-integragen-sequencing

The Greater Paris University Hospitals (AP-HP) and IntegraGen announced today an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives. This three-year research partnership aligns with a major objective of AH-HP’s 2015-2019 Strategic Plan related to (…)  » 

10 June 2016

Commentaries on presentation of miR-31-3p data at ASCO 2016

06 June 2016

IntegraGen Presents Positive Data at 2016 ASCO Meeting on the Role of microRNA Biomarker miR-31-3p

IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.

(…)  » 

19 May 2016

Results of study focusing on miR-31-3p expression in patients enrolled in FIRE-3 trial to be presented during ASCO 2016

The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…)  » 

08 April 2016

IntegraGen announces 2015 financial results

integragen

IntegraGen today announced its financial results for the year ended 31 December 2015.

The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 7, 2016.

Click here to view press release

Page 8/11 « 1 … 5 6 7 8 9 10 11 »
News and Events
  • Press Releases
  • Latest News
  • Scientific publications
  • Upcoming Events
    • SÉMINAIRE DE GÉNÉTIQUE CLINIQUE À ANGERS
    • Belgian Society for Human Genetics (BeSHG)
Stay in touch with us!
SUBSCRIBE TO OUR NEWSLETTER
  • Integragen IntegraGen is a high-tech company with renown expertise in genomic testing and software solutions for research and clinical applications.
  • Areas of Interest
    • Clinical Research
    • Basic and Human Genetic Research
    • Agrigenomics
    • Microbial Genomics
  • Genomic services
    • Transcriptomics
    • Epigenomics
    • DNA Sequencing
    • NGS Test for Cancer Research
    • SNP Genotyping
  • Bioinformatics
    • MERCURY
    • SIRIUS
    • GALILEO
    • GECO
  • About Us
    • Company Overview
    • Management Team
    • Careers
    • Board of Directors
  • News and Events »
  • Investors »
  • Contact Us »
  • General Terms and Conditions of Services .
  • Home .
  • Legal Policy .
  • Site map .
Copyright © 2023 IntegraGen. All rights reserved. »
Logo OncoKDM
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Change my preferenceACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-advertisement1 yearThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
pll_language1 yearThis cookie is set by Polylang plugin for WordPress powered websites. The cookie stores the language code of the last browsed page.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
CookieDurationDescription
_gat1 minuteThis cookies is installed by Google Universal Analytics to throttle the request rate to limit the colllection of data on high traffic sites.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
vuid2 yearsThis domain of this cookie is owned by Vimeo. This cookie is used by vimeo to collect tracking information. It sets a unique ID to embed videos to the website.
_ga2 yearsThis cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_gid1 dayThis cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visted in an anonymous form.
SAVE & ACCEPT
Powered by CookieYes Logo